2025.01.08
Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company’s American Depository Shares (ADSs) ROCKVILLE, MD, January 8, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced […]
2025.01.06
Givastomig: a Claudin 18.2 (“CLDN18.2”) x 4-1BB bispecific antibody, will be the lead clinical program following the Company’s portfolio prioritization The Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is […]
2024.11.21
The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024 ROCKVILLE, MD, November 21, 2024 – I-Mab (NASDAQ: IMAB, the “Company”), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Piper Sandler 36th […]
2024.11.14
Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 Estimated cash runway into 2027, based on $184.4 million in cash and […]
2024.11.06
ROCKVILLE, MD, November 6, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed as the Company’s permanent Chief Executive Officer (“CEO”) effective November 1, 2024. Dr. Fu […]
2024.10.31
ROCKVILLE, MD, October 31, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. […]
2024.10.30
– Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024 ROCKVILLE, MD, October 30, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced […]
2024.10.28
ROCKVILLE, MD, October 28, 2024 – I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024. Event Details Meeting […]
2024.09.16
Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levels The recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; givastomig was well tolerated up to the highest […]
2024.09.10
Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients Randomized Phase 2 study of uliledlimab in combination with pembrolizumab plus chemotherapy expected to begin in 1H 2025 ROCKVILLE, MD, September 11, 2024 […]